Phase I
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Although clinical trials are often performed throughout different parts of the world, often their demographic makeup—the gender, age and race of participants—has a certain kind of uniformity.
Biotech companies from across the globe are posting strong data at the Virtual Edition of the 25th European Hematology Association (EHA25) Annual Congress. Below is a roundup of some of the news coming out of the virtual conference.
Decentralized clinical trials gained a foothold in the pharmaceutical industry amidst the COVID-19 pandemic and will continue to be used once the pandemic ends, according to panelists at BIO 2020, speaking Thursday in a virtual session.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer’s Drug
Denali Therapeutics and its development partner Sanofi announced data from its Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
On Monday, Sarepta Therapeutics announced positive results from a small study of SRP-9003, its gene therapy for limb-girdle muscular dystrophy Type 2E (LGMD2E).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 8, 2020.
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
PRESS RELEASES